The Glycemic Efficacy and Safety Profile of Gliptins: Updated Data in 2020
Keywords:
DPP-4 inhibitors, vildagliptin, alogliptin, cardiovascular benefits, safety and efficacyAbstract
Background: The earlier update on the safety of gliptins published in 2018 showed that dipeptidyl peptidase-4 (DPP-4)
inhibitors have good tolerance and safety profile even in susceptible populations. This review provides recent updates
(2018‑2020) on the glycemic efficacy and safety profile of gliptins, cardiovascualr safety of gliptins, and their role when used
early in diabetes therapy. Summary: DPP-4 inhibitors or gliptins is an established class of oral antidiabetic agents in the
management of type 2 diabetes with proven efficacy and safety profiles in adults, elderly and young patients. The excellent
safety and efficacy of DPP-4 inhibitors are established in type 2 diabetes management even in fragile populations and
individuals with varying degrees of renal dysfunction. DPP-4 inhibitors are associated with a good tolerability profile and
reduced risk of hypoglycemia. Studies have not shown the involvement of gliptins in cardiovascular adverse events and are
considered to be safe for use in terms of cardiovascular events.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
